Coherus Oncology (CHRS) Cash & Current Investments (2012 - 2026)
Coherus Oncology recorded quarterly Cash & Current Investments of $167.0 million in Q1 2026, down 2.95% quarter-over-quarter from $172.1 million in Q4 2025, and up 102.7% year-over-year from $82.4 million in Q1 2025.
Coherus Oncology's Cash & Current Investments history runs 15 years deep, the most recent figure standing at $167.0 million for Q1 2026.
- In Q1 2026, Cash & Current Investments rose 102.7% year-over-year to $167.0 million; the TTM figure through Mar 2026 stood at $167.0 million (up 102.7% YoY), while the FY2025 annual figure was $172.1 million, up 36.62% from the prior year.
- Cash & Current Investments came in at $167.0 million for Q1 2026 at Coherus Oncology, down from $172.1 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $325.7 million in Q1 2022 to a low of $82.4 million in Q1 2025.
- A 5-year average of $182.1 million and a median of $167.0 million in 2026 frame the typical range for Cash & Current Investments.
- Across the five-year window, Cash & Current Investments jumped 102.81% in 2024 and slumped 68.28% in 2025, its largest moves.
- Coherus Oncology's Cash & Current Investments stood at $191.7 million in 2022, then sank by 38.57% to $117.7 million in 2023, then advanced by 7.0% to $126.0 million in 2024, then soared by 36.62% to $172.1 million in 2025, then decreased by 2.95% to $167.0 million in 2026.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $167.0 million, $172.1 million, and $191.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 2.13 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 7.25 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Coherus Oncology | 216.87 Mn | 49.83 Mn | 8.50 Mn | 167.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 167.05 Mn |
| Dec 31, 2025 | 172.13 Mn |
| Sep 30, 2025 | 191.66 Mn |
| Jun 30, 2025 | 237.64 Mn |
| Mar 31, 2025 | 82.41 Mn |
| Dec 31, 2024 | 125.99 Mn |
| Sep 30, 2024 | 97.69 Mn |
| Jun 30, 2024 | 159.24 Mn |
| Mar 31, 2024 | 259.78 Mn |
| Dec 31, 2023 | 117.75 Mn |
| Sep 30, 2023 | 131.08 Mn |
| Jun 30, 2023 | 144.71 Mn |
| Mar 31, 2023 | 128.09 Mn |
| Dec 31, 2022 | 191.68 Mn |
| Sep 30, 2022 | 286.81 Mn |
| Jun 30, 2022 | 275.48 Mn |
| Mar 31, 2022 | 325.68 Mn |
| Dec 31, 2021 | 417.20 Mn |
| Sep 30, 2021 | 468.71 Mn |
| Jun 30, 2021 | 454.42 Mn |
| Mar 31, 2021 | 399.50 Mn |
| Dec 31, 2020 | 541.16 Mn |
| Sep 30, 2020 | 503.43 Mn |
| Jun 30, 2020 | 456.50 Mn |
| Mar 31, 2020 | 193.25 Mn |
| Dec 31, 2019 | 177.67 Mn |
| Sep 30, 2019 | 170.49 Mn |
| Jun 30, 2019 | 111.92 Mn |
| Mar 31, 2019 | 96.43 Mn |
| Dec 31, 2018 | 72.36 Mn |
| Sep 30, 2018 | 117.17 Mn |
| Jun 30, 2018 | 29.86 Mn |
| Mar 31, 2018 | 95.16 Mn |
| Dec 31, 2017 | 126.91 Mn |
| Sep 30, 2017 | 150.05 Mn |
| Jun 30, 2017 | 118.33 Mn |
| Mar 31, 2017 | 174.82 Mn |
| Dec 31, 2016 | 60,000.00 |
| Sep 30, 2016 | 159.68 Mn |
| Jun 30, 2016 | 220.92 Mn |
| Mar 31, 2016 | 179.56 Mn |
| Dec 31, 2015 | 158.23 Mn |
| Sep 30, 2015 | 153.69 Mn |
| Jun 30, 2015 | 206.09 Mn |
| Mar 31, 2015 | 115.14 Mn |
| Dec 31, 2014 | 150.39 Mn |
| Sep 30, 2014 | 100.88 Mn |
| Jun 30, 2014 | 108.87 Mn |
| Mar 31, 2014 | 56.32 Mn |
| Dec 31, 2013 | 39.55 Mn |
| Sep 30, 2013 | 34.72 Mn |
| Dec 31, 2012 | 14.55 Mn |